Microbial Metabolites: Critical Regulators in NAFLD.

Area of Science:

• Gastroenterology and Hepatology
• Microbiology
• Metabolomics

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a global health concern, representing the most prevalent form of chronic liver disease.
• The gut microbiota plays a critical role in NAFLD pathogenesis through nutrient fermentation, immune system interaction, and intestinal barrier function.
• Microbial metabolites produced in the gut can translocate to the liver, impacting hepatic signaling pathways.

Purpose of the Study:

• To review the influence of key gut microbial metabolites on NAFLD.
• To explore therapeutic strategies targeting the gut-liver axis and microbial metabolite modulation for NAFLD treatment.

Main Methods:

• Literature review focusing on the role of short-chain fatty acids, trimethylamine-N-oxide, bile acids, endogenous ethanol, and indole in NAFLD.
• Analysis of current and emerging therapies for NAFLD related to gut microbiota modulation.

Main Results:

• Specific microbial metabolites, including SCFAs, TMAO, bile acids, ethanol, and indole, are implicated in NAFLD development and progression.
• Various interventions, such as antibiotics, prebiotics, probiotics, bile acid regulation, and FMT, show potential for modulating the gut microbiota and its metabolites to treat NAFLD.

Conclusions:

• The intricate interplay between microbial metabolites and NAFLD pathogenesis is crucial for understanding and treating the disease.
• Targeting the gut-liver axis and modulating gut microbial metabolites represents a promising therapeutic avenue for NAFLD.